特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
465223

褥瘡:パイプライン製品の分析

Pressure Ulcers - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 32 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.70円
褥瘡:パイプライン製品の分析
出版日: 2020年08月31日
発行: Global Markets Direct
ページ情報: 英文 32 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

褥瘡とは、皮膚および下層組織を壊す損傷です。体の中で褥瘡を発症するリスクが最も高い場所は、体脂肪で広く覆われておらず、ベッドや車いすなどの支持面と直接接触している部分です。原因は、継続的な圧迫や摩擦およびズレです。治療には抗生物質や栄養剤を使います。

当レポートでは、褥瘡の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

褥瘡;概要

治療薬の開発

  • パイプライン製品;概要
  • 企業別の製品
  • 企業で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • EyeGene Inc
  • Izun Pharmaceuticals Corp
  • MediWound Ltd
  • NovaLead Pharma Pvt Ltd
  • RegeneRx Biopharmaceuticals Inc
  • RMB-Research GmbH

薬剤プロファイル

  • AG-100
  • EG-Decorin
  • EscharEx
  • IZN-6D4
  • NLP-328
  • RGN-137
  • Statmicoll
  • 褥瘡向け幹細胞療法

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

図表

図表

List of Tables

List of Tables

  • Number of Products under Development for Pressure Ulcers, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pressure Ulcers - Pipeline by EyeGene Inc, H2 2020
  • Pressure Ulcers - Pipeline by MimeTech Srl, H2 2020
  • Pressure Ulcers - Pipeline by NovaLead Pharma Pvt Ltd, H2 2020
  • Pressure Ulcers - Pipeline by Obatala Sciences Inc, H2 2020
  • Pressure Ulcers - Pipeline by Shionogi & Co Ltd, H2 2020
  • Pressure Ulcers - Pipeline by Topadur Pharma AG, H2 2020
  • Pressure Ulcers - Dormant Projects, H2 2020
  • Pressure Ulcers - Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Pressure Ulcers, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
目次
Product Code: GMDHC12427IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pressure Ulcers - Pipeline Review, H2 2020, provides an overview of the Pressure Ulcers (Dermatology) pipeline landscape.

Pressure ulcers are an injury that breaks down the skin and underlying tissue. The parts of the body most at risk of developing pressure ulcers are those that are not covered by a large amount of body fat and are in direct contact with a supporting surface (bed or a wheelchair). Causes include continuous pressure, friction and shear. Treatment includes antibiotics and nutrition.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pressure Ulcers - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Pressure Ulcers (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pressure Ulcers (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pressure Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 2 and 4 respectively.

Pressure Ulcers (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pressure Ulcers (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Pressure Ulcers (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pressure Ulcers (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pressure Ulcers (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pressure Ulcers (Dermatology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pressure Ulcers (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pressure Ulcers (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Pressure Ulcers - Overview
  • Pressure Ulcers - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Pressure Ulcers - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Pressure Ulcers - Companies Involved in Therapeutics Development
  • EyeGene Inc
  • MimeTech Srl
  • NovaLead Pharma Pvt Ltd
  • Obatala Sciences Inc
  • Shionogi & Co Ltd
  • Topadur Pharma AG
  • Pressure Ulcers - Drug Profiles
  • EG-Decorin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NLP-328 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SR-0379 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy for Pressure Ulcers - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TOPN-53 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • udonitrectag - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Pressure Ulcers - Dormant Projects
  • Pressure Ulcers - Discontinued Products
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.